OBJECTIVE: To evaluate the feasibility and efficacy of robotic-assisted management of epithelial ovarian cancer. METHODS: Retrospective review of robotic-assisted or abdominal ovarian cancer cases presenting with pelvic mass, initial staging, or debulking after neoadjuvant chemotherapy performed by a single surgeon (2008-2012). Patient characteristics and outcomes were compared using chi-squared or Student's t-tests. RESULTS: There were 63 robotic and 26 abdominal cases. Patient characteristics were similar for age, uterine weight, and BMI, with prior abdominal surgery more common in the abdominal group (p=0.0257). Robotic operative time was longer (p<0.0001), while blood loss (p<0.0001) and hospital stay (p=0.0009) were reduced. Major complication rates (16% vs. 23%, p=0.4209) and lymphadenectomy yields (13 vs. 11 nodes, p=0.2310) were similar. Neoadjuvant chemotherapy was more common in the robotic group (52% vs. 15%, p=0.0013). Residual disease rates for all cases (73% vs. 50%, p=0.880) and for Stage II-IV cases (61% vs. 40%, p=0.929) were equivalent. Follow-up was longer for the abdominal group; however, an equivalent percentage of patients had at least 1 year of follow-up (57% vs. 77%, p=0.0789). At 1 year, survival and no evidence of disease (NED) rates were equivalent for all cases (survival: 97% vs. 90%, p=0.2501; NED: 81% vs. 85%, p=0.6773) and for Stage II-IV cases (survival: 96% vs. 88%, p=0.3080; NED: 76% vs. 81%, p=0.6920). CONCLUSIONS: A robotic approach for the management of epithelial ovarian cancer, including patients treated with neoadjuvant chemotherapy, is feasible and effective. Debulking, recurrence, and survival rates were similar to laparotomy at 1 year.
OBJECTIVE: To evaluate the feasibility and efficacy of robotic-assisted management of epithelial ovarian cancer. METHODS: Retrospective review of robotic-assisted or abdominal ovarian cancer cases presenting with pelvic mass, initial staging, or debulking after neoadjuvant chemotherapy performed by a single surgeon (2008-2012). Patient characteristics and outcomes were compared using chi-squared or Student's t-tests. RESULTS: There were 63 robotic and 26 abdominal cases. Patient characteristics were similar for age, uterine weight, and BMI, with prior abdominal surgery more common in the abdominal group (p=0.0257). Robotic operative time was longer (p<0.0001), while blood loss (p<0.0001) and hospital stay (p=0.0009) were reduced. Major complication rates (16% vs. 23%, p=0.4209) and lymphadenectomy yields (13 vs. 11 nodes, p=0.2310) were similar. Neoadjuvant chemotherapy was more common in the robotic group (52% vs. 15%, p=0.0013). Residual disease rates for all cases (73% vs. 50%, p=0.880) and for Stage II-IV cases (61% vs. 40%, p=0.929) were equivalent. Follow-up was longer for the abdominal group; however, an equivalent percentage of patients had at least 1 year of follow-up (57% vs. 77%, p=0.0789). At 1 year, survival and no evidence of disease (NED) rates were equivalent for all cases (survival: 97% vs. 90%, p=0.2501; NED: 81% vs. 85%, p=0.6773) and for Stage II-IV cases (survival: 96% vs. 88%, p=0.3080; NED: 76% vs. 81%, p=0.6920). CONCLUSIONS: A robotic approach for the management of epithelial ovarian cancer, including patients treated with neoadjuvant chemotherapy, is feasible and effective. Debulking, recurrence, and survival rates were similar to laparotomy at 1 year.
Authors: Semiramis L Carbajal-Mamani; David Schweer; Merry J Markham; Ashwini K Esnakula; Joseph R Grajo; Jacqueline C Castagno; Joel Cardenas-Goicoechea Journal: Obstet Gynecol Sci Date: 2020-02-10
Authors: J S M Zimmermann; J C Radosa; M P Radosa; P Sklavounos; P A Schweitzer; E F Solomayer Journal: Arch Gynecol Obstet Date: 2020-11-17 Impact factor: 2.344